Vanda Pharmaceuticals (VNDA) Tops Q4 Views

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. MU
4. SPY
5. ACN

6. IBM
7. META
8. PFE
9. TSLA
10. DPZ

Get Alerts VNDA Hot Sheet

Price: $6.05 +0.83%

EPS Growth %: -30.4%

Financial Fact:
Net income (loss): -430K

Today's EPS Names:
MAYS, CRMT, REPL, More

Join SI Premium – FREE

Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 EPS of $0.36, $0.35 better than the analyst estimate of $0.01. Revenue for the quarter came in at $53.04 million versus the consensus estimate of $51.7 million.

GUIDANCE:

2019 Financial Guidance

Vanda expects to achieve the following financial objectives in 2019:

Full Year 2019 Guidance
Combined net product sales from both HETLIOZ® and Fanapt®	$215 to $225 million
HETLIOZ® net product sales	$137 to $143 million
Fanapt® net product sales	$78 to $82 million
Year-end 2019 Cash	Greater than $260 million

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

Create E-mail Alert Related Categories

Earnings, Guidance

Related Entities

Earnings

Sign up for StreetInsider Free!

Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!